University of Birmingham
Which factors predict early discontinuation of antifibrotics in idiopathic pulmonary fibrosis?
Abstract
dc:description.abstractIntroduction: Pirfenidone and nintedanib are recommended in idiopathic pulmonary fibrosis (IPF). Randomised controlled trials have shown discontinuation rates of 14-33%; clinical audit in our regional centre showed a rate of 18.4%. I aimed to establish the main factors, which predict early discontinuation of antifibrotics using a mixed methodology approach. Methods: I collected data on 170 patients with IPF (2012-16) prescribed pirfenidone (n=139) or nintedanib (n=31). Retrospective data was collected including demographics, social factors, diagnostics, antifibrotic prescribed, treatment duration and side-effects. We undertook focus groups and patient interviews, which were analysed thematically. Results: Commonest side-effects were nausea/vomiting (50%) and appetite loss (40%; pirfenidone) and diarrhoea (79%) and weight loss (25%; nintedanib). DLCO ≤40% (OR=2.46) increased risk of early discontinuation at 30-days, with males (OR=0.41) and skin side-effects (OR=0.09) associated with reduced risk. At 90-days, deconditioning side effects (OR=2.58) increased risk of early discontinuation, whereas males (OR=0.39) and gastrointestinal side effects (OR=0.40) reduced risk. Thematic analysis suggested side-effects were tolerable and social factors were not considered barriers by patients. Conclusion: Female gender and DLCO ≤40% were predictors of early discontinuation, compared with social factors. Low DLCO has been shown to predict increased mortality therefore progressive disease would increase risk of early discontinuation.
Degree
thesis:*- Name dc:type.qualificationname
- m_sc
- Level dc:type.qualificationlevel
- m_sc
- Grantor dc:publisher.institution
- University of Birmingham
- Year dc:date.issued
- 2020
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Bhomra, Parminder Singh
Subjects
dc:subject × 1Rights
- Language dc:language.dcterms_iso639_2
- eng